PillRx only · For Suspension · Oral
Famotidine
Famotidine
3 ACTIVE SUPPLIERS — US
openFDA · updated weekly
US3 NDCs
3 active makers
3 active makers
UKComing
soon
soon
CAComing
soon
soon
AUComing
soon
soon
EUComing
soon
soon
US acquisition costNADAC · per unit
Average across 1 priced NDCs. A benchmark of pharmacy acquisition cost — not a retail quote.
$0.137
Latest avg · Jul 22, 2026
-36%
Since Dec 17, 2025
3
Active US suppliers
67%
Top-2 supplier share*
Medicaid dispensing volumeSDUD · per quarter
Prescriptions dispensed under Medicaid (fee-for-service + managed care), summed nationally. The closest free proxy to sales volume — Medicaid only, not all-payer.
39K
Rx · 2026 Q1
2.8M
Units dispensed
-29%
Rx vs. year ago
5
Quarters · since 2025 Q1
Who makes it3 active · 0 exited
US labelers as registered with FDA. Repackagers relabel another company's product; share* is of listed packages, not sales.
| Labeler | Type | Packages | Status |
|---|---|---|---|
| Dr.Reddy's laboratories Limited | unknown | 1 | SUPPLYING |
| Ajanta Pharma USA Inc. | unknown | 1 | SUPPLYING |
| Lupin Pharmaceuticals,Inc. | unknown | 1 | SUPPLYING |
Regulatory & supply eventsFDA · US
Shortages, recalls, and registration changes attached to this drug concept.
- Jun 20, 2014RECALLRecall (Class III): Famotidine for Oral Suspension, USP 40 mg/5 mL, Rx Only, Cherry-Banana-Mint Flavored, Not for Injection, Manufactured b…
Failed Impurity/Degradation Specification; 12-month stability time point — Recalling firm: Novel Laboratories, Inc. — Nationwide